PubMed Health⌕ Search

PubMed · 9136072

p-value adjustments for subgroup analyses.

Abstract

The analysis of data from clinical trials often includes subgroup analyses, which are performed to examine the treatment effect within various sets of patients based on baseline and/or demographic variables. The goals of these analyses are to establish the consistency of the results across the subgroups and to identify important prognostic factors. The p-values for such analyses are usually presented without any adjustment for the multiple analyses: This approach has been criticized because of the possibility of misleading false positives. Conservative approaches have been proposed to resolve this problem; however, these approaches are usually so conservative that significant results are rarely observed after adjustment. Here an approximate technique for use when the variable of interest has a normal distribution is presented.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D R Bristol. 1997. p-value adjustments for subgroup analyses.. https://doi.org/10.1080/10543409708835189

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Optimal two-stage designs for clinical trials based on safety and efficacy.

In clinical trials designed to evaluate treatment efficacy, it is common practice to terminate a treatment arm in which the observed rate of an adverse event is unacceptably high. This practice may be formalized by a group-sequential test based on a multivariate outcome including both adverse and efficacy events. Recently, Thall and Cheng proposed a family of tests for randomized trials of an experimental treatment versus a standard where patient outcome is bivariate with entries characterizing efficacy and safety. The test is motivated by the idea that clinically meaningful improvements over the standard may be characterized by a two-dimensional parameter quantifying trade-offs between efficacy and safety. We provide optimal two-stage designs based on this test that minimize either the mean sample size under the null hypothesis of no treatment difference, or the maximum sample size if the trial continues to a second stage. A more general group-sequential version of the design also is described, an illustration is provided, and application to the special case of single-arm phase II trials is discussed.

Clinical Trials as Topic↗